Welcome to our dedicated page for Moelis & Co SEC filings (Ticker: MC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the advisory-fee breakout or understanding why Moelis & Co’s compensation ratio swings 500 basis points can take hours inside a 300-page 10-K. Investors also track when partners buy shares ahead of blockbuster deal announcements. If you have ever typed “Moelis & Co insider trading Form 4 transactions” and been buried in legal jargon, you know the challenge.
Stock Titan solves this with AI-powered summaries that translate complex footnotes into plain English. Our platform streams “Moelis & Co Form 4 insider transactions real-time,” flags any unusual equity awards, and links them to the next “Moelis & Co 8-K material events explained.” Need the latest “Moelis & Co quarterly earnings report 10-Q filing”? We surface revenue by region, backlog trends and segment margins in one click. Annual diligence is simpler too—our tool offers a “Moelis & Co annual report 10-K simplified” view that highlights advisory fee concentration, regulatory capital and partnership distributions. Even executive pay is clearer: the “Moelis & Co proxy statement executive compensation” section breaks down cash versus equity and compares it to peers.
Use the data the way professionals do:
- Spot headcount and expense ratios before the call
- Monitor “Moelis & Co executive stock transactions Form 4” for pipeline sentiment
- Dive into “Moelis & Co earnings report filing analysis” to benchmark deal activity
- Leverage “understanding Moelis & Co SEC documents with AI” to save research hours
Every filing, from 10-K to 8-K, is refreshed the moment EDGAR updates, so you never miss a disclosure that moves the share price. Complex documents become actionable insights—no manual page-turning required.
Moelis & Company reported stronger Q3 2025 results. Revenue rose to $356.9 million from $273.8 million a year ago, lifting operating income to $48.3 million from $15.6 million. Net income attributable to the company increased to $53.4 million versus $16.9 million, with diluted EPS of $0.67 compared to $0.22. Year to date, revenue reached $1,028.9 million versus $755.8 million, and diluted EPS was $1.84 versus $0.61.
Operating cash flow for the first nine months was $237.6 million, up from $112.1 million, driven by higher earnings. Cash and cash equivalents were $281.6 million as of September 30, 2025, while investments expanded to $366.8 million. The company realized a $19.1 million gain on a partial sale of its MA Financial stake in Q3 and received $2.3 million of dividends year to date. Moelis continued returning capital with quarterly dividends of $0.65 per Class A share and repurchased $28.5 million of shares year to date. Shares outstanding were 73,996,339 Class A and 4,324,418 Class B as of October 15, 2025.
Moelis & Company furnished an update on October 29, 2025. The company issued a press release announcing financial results for the third quarter ended September 30, 2025, and made an updated investor presentation available on its Investor Relations website.
The press release is attached as Exhibit 99.1 and, along with the presentation update, is furnished but not filed.
Nick Riehl, an officer and director at Moelis & Co (MC), reported receipt of restricted stock units (RSUs) on 09/18/2025. The Form 4 shows three grants labelled as 2023 Long Term Incentive RSUs, 2024 Incentive RSUs, and 2024 Long Term Incentive RSUs issued as dividend equivalents and recorded as acquisitions on that date. Each RSU represents the right to receive either a share of Class A common stock or cash equal to the share value upon settlement. The filing records beneficial ownership amounts of 979.01, 246.42, and 327.88 shares respectively after the transactions, with a reported price of $0 because these are dividend-equivalent RSUs that vest with the underlying awards.
Moelis & Co (MC) director Kenneth Shropshire reported receipt of restricted stock units on 09/18/2025. The Form 4 shows three dividend-equivalent RSU issuances tied to prior grants: 2024 Annual RSUs, 2025 Annual RSUs, and 2025 Elective RSUs. The filing lists numeric values associated with each line: 17.64 (2024 Annual), 14.72 (2025 Annual), and 1.74 (2025 Elective), and reports the amount of securities beneficially owned following the transactions as 2,127.9, 1,775.72, and 209.74 respectively. Shropshire is identified as a director and the Form 4 was signed by an attorney-in-fact, Osamu Watanabe, on 09/19/2025.
Osamu Watanabe, General Counsel and Secretary of Moelis & Co (MC), reported receipt of dividend-equivalent Restricted Stock Units (RSUs) on 09/18/2025. The Form 4 shows Incentive RSUs issued as dividend equivalents tied to prior unvested grants from 2020 through 2025 and that each dividend-equivalent RSU will vest with its underlying award. Reported per-grant resulting beneficial ownership figures following the issuance include 2,202.52, 4,154.56, 5,941.42, 6,272.53, and 6,508.04 shares of Class A common stock. The form is signed by Mr. Watanabe on 09/19/2025.
Eric Cantor, Vice Chairman and Director of Moelis & Co (MC), received dividend-equivalent Restricted Stock Units (RSUs) that increased his beneficial ownership on 09/18/2025. The Form 4 shows grant-like entries for dividend-equivalent Incentive RSUs tied to prior award years 2020 through 2024 and for 2024 Long Term Incentive RSUs. Reported incremental amounts include 60.74, 114.54, 215.48, 221.02, 130.81 and 54.5 units respectively, with resulting beneficial ownership totals shown as 7,325.74, 13,815.16, 25,990.31, 26,658.28, 15,777.26 and 6,573 for each corresponding award line. Each RSU represents the right to receive either a share of Class A common stock or cash equal to its fair market value, and the dividend-equivalent RSUs will vest concurrent with the underlying unvested awards.
Thorold Barker, a director of Moelis & Co (MC), received 2025 Annual Restricted Stock Units totaling 1,614.38 units on 09/18/2025. The Form 4 shows these RSUs were issued as dividend equivalents on underlying Annual RSUs granted July 14, 2025, and will vest concurrently with those underlying awards. Each RSU represents the right to receive one share of Class A common stock. The reported grant lists a price of $13.38 and the filing was signed by an attorney-in-fact on 09/19/2025.
Christopher Callesano, Chief Financial Officer of Moelis & Co (MC), reported issuances of dividend-equivalent Restricted Stock Units (RSUs) on 09/18/2025. The Form 4 shows dividend-equivalent Incentive RSUs credited for multiple grant vintages: 2020 (3.65 RSUs; 439.7 shares held after), 2021 (6.3 RSUs; 760.36), 2022 (14.9 RSUs; 1,797.35), 2023 (13.65 RSUs; 1,646.33), and 2024 (13.62 RSUs; 1,642.48). Each RSU represents the right to receive either one share of Class A common stock or a cash amount equal to the fair market value on settlement. The entries are reported as acquisitions (code A) with a reported price of $0, and the dividend-equivalent RSUs vest concurrently with the underlying unvested Incentive RSUs.
Moelis & Co (MC) director Louise Mirrer reported receipt of restricted stock units (RSUs) on 09/18/2025. The Form 4 lists three non-derivative RSU entries: 1,253.3, 38.76, and 1,695.05 RSUs, each identified as dividend-equivalent RSUs that will vest concurrently with their underlying annual RSUs. The filing was executed by an attorney-in-fact and signed 09/19/2025. No option exercises or derivative transactions are reported. The Form 4 reflects additional equity compensation issued to a director rather than cash transactions or disposals.
Moelis & Co (MC) director Laila Worrell reported acquisitions of restricted stock units on 09/18/2025. The Form 4 shows three separate awards of dividend-equivalent RSUs tied to previously granted awards: 2024 Annual RSUs, 2025 Annual RSUs and 2025 Elective RSUs. Each RSU represents the right to receive one share of Class A common stock and the dividend-equivalent RSUs will vest concurrently with the underlying RSUs. The Form is signed by an attorney-in-fact on 09/19/2025.
FAQ
What is the current stock price of Moelis & Co (MC)?
What is the market cap of Moelis & Co (MC)?
